Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026Cancer Research

Abstract B003: Pan-Cancer Systematic Meta-Analysis of RAS Oncogene Mutational Landscapes and Therapeutic Vulnerabilities

View Full Paper
Ask AI
Bookmark
Share

Authors

SKShivi KumarDRDeirde Richardson

Discussion

Loading...

Member takes

Overview

Meta-analysis uncovers RAS mutation patterns in various cancers, suggesting unique therapeutic vulnerabilities for tailored treatment.

Key Points

  • To characterize the landscape of RAS mutations across cancers and assess their therapeutic implications.
  • Performed a systematic meta-analysis of over 30,000 patient samples from TCGA, ICGC, and CPTAC repositories.
  • Applied random-effects meta-regression and survival modeling to identify mutational hotspots.
  • Conducted subgroup analyses on colorectal, pancreatic, lung, and melanoma cancer types.
  • Identified cancer-specific and pan-cancer RAS mutational hotspots like KRAS G12C and NRAS Q61.
  • Revealed distinct mutation-response patterns related to targeted therapies and immunotherapy across different cancers.
  • Provided insights for precision oncology, aiding drug development and clinical trial design.

Cite This Study

Kumar et al. (2026) studied this question.

synapsesocial.com/papers/69abc1b45af8044f7a4ea98bhttps://doi.org/10.1158/1538-7445.rasoncother26-b003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 3988: Beyond G12C: Pan-cancer landscape and co-mutational architecture of rare RAS alleles across 211,526 patients2026
  2. 2Abstract IA008: Pancreas cancer: Genomics, RAS therapeutics and clinical landscape2026
  3. 3Abstract IA007: Response and resistance to RAS blockade in solid tumors and beyond2026
  4. 4Abstract B076: Clinical and Molecular Characteristics of <i>KRASQ61</i> Mutated Pancreatic Cancer and Other Gastrointestinal Malignancies2025
  5. 5Abstract 1216: Pan-RAS inhibition by a tumor-targeted biotherapeutic2024